Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

The oncogene Gankyrin is expressed in testicular cancer and contributes to cisplatin sensitivity in embryonal carcinoma cells

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Are cancer patients better off if they participate in clinical trials? A mixed methods study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Physical function in patients newly diagnosed with multiple myeloma; a Danish cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Reliable cell and tissue morphology-based diagnosis of endemic Burkitt lymphoma in resource-constrained settings in Ghana

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. An In Vitro Differentiation Protocol for Human Embryonic Bipotential Gonad and Testis Cell Development

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Age-related changes in human Leydig cell status

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Novel functions of the luteinizing hormone/chorionic gonadotropin receptor in prostate cancer cells and patients

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Maria E Camacho-Moll
  • Joni Macdonald
  • L H J Looijenga
  • Michael P Rimmer
  • Roland Donat
  • John A Marwick
  • C J Shukla
  • Neil Carragher
  • Anne Jørgensen
  • Rod T Mitchell
View graph of relations

BACKGROUND: Testicular germ cell cancer (TGCC) develops from pre-malignant germ neoplasia in situ (GCNIS) cells. GCNIS originates from fetal gonocytes (POU5F1+/MAGE-A4-), which fail to differentiate to pre-spermatogonia (POU5F1-/MAGE-A4+) and undergo malignant transformation. Gankyrin is an oncogene which has been shown to prevent POU5F1 degradation and specifically interact with MAGE-A4 in hepatocellular carcinoma (HCC) cells. We aimed to investigate the role of Gankyrin in progression from gonocyte to pre-invasive GCNIS and subsequent invasive TGCC.

METHODS: We determined Gankyrin expression in human fetal testicular tissue (gestational weeks 9-20; n = 38), human adult testicular tissue with active spermatogenesis (n = 9), human testicular tissue with germ cell maturation delay (n = 4), testicular tissue from patients with pre-invasive GCNIS (n = 6), and invasive TGCC including seminoma (n = 6) and teratoma (n = 7). Functional analysis was performed in-vitro by siRNA knock-down of Gankyrin in the NTera2 cells (derived from embryonal carcinoma).

RESULTS: Germ cell expression of Gankyrin was restricted to a sub-population of prespermatogonia in human fetal testes. Nuclear Gankyrin was also expressed in GCNIS cells of childhood and adult pre-invasive TGCC patients, and in GCNIS from seminoma and non-seminoma patients. Cytoplasmic expression was observed in seminoma tumour cells and NTera2 cells. Gankyrin knock-down in NTera2 cells resulted in an increase in apoptosis mediated via the TP53 pathway, whilst POU5F1 expression was unaffected. Furthermore, Gankyrin knock-down in NTera2 cells increased cisplatin sensitivity with an increase in cell death (13%, p < 0.05) following Gankyrin knock-down, when compared to cisplatin treatment alone, likely via BAX and FAS. Our results demonstrate that Gankyrin expression changes in germ cells during normal transition from gonocyte to prespermatogonia. In addition, changes in Gankyrin localisation are associated with progression of pre-invasive GCNIS to invasive TGCC. Furthermore, we found that Gankyrin is involved in the regulation of NTera2 cell survival and that a reduction in Gankyrin expression can modulate cisplatin sensitivity.

CONCLUSIONS: These results suggest that manipulation of Gankyrin expression may reduce the cisplatin dose required for the treatment of TGCC, with benefits in reducing dose-dependent side effects of chemotherapy. Further studies are required in order to assess the effects of modulating Gankyrin on GCNIS/TGCC using in vivo models.

Original languageEnglish
JournalBMC Cancer
Volume19
Issue number1
Pages (from-to)1124
ISSN1471-2407
DOIs
Publication statusPublished - 19 Nov 2019

ID: 59605601